Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Neuroendocrine 2Carcinoma 1Carcinoid Tumor 1

Interventions

Everolimus 3Sunitinib 2Octreotide 2repotrectinib 1pralsetinib 1pasireotide 1lutetium Lu 177 dotatate 1epothilone B 1cixutumumab 1belinostat 1azaspirane 1avelumab 1Radiotherapy 1Lutetium-177 1Etoposide 1Doxorubicin 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × azaspirane × Endocrine × Clear all
NCT00388063 2007-12-21

Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Callisto Pharmaceuticals

Phase 2 Completed
55 enrolled
Endocrine

Carcinoid Tumor, Carcinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡